A Win for Science
A new gene therapy drug was approved by the FDA to use in adults with non-Hodgkin’s lymphoma whose past treatments have failed. Yescarta, the therapy, will transform the cancer patients' cells into attacker cells to combat the cancer in their body. During the trial run of Yescarta, side effects were severe, and some patients died from them, but those are patients who have undergone two unsuccessful rounds of chemotherapy. The gene therapy is their last chance at beating their disease. The therapy will not instantly be widespread because doctors need to be trained in how to administer the drug.
For more information, click here.